The stock of Legend Biotech Corp ADR (LEGN) has gone down by -0.92% for the week, with a -2.88% drop in the past month and a -10.25% drop in the past quarter. The volatility ratio for the week is 6.09%, and the volatility levels for the past 30 days are 4.63% for LEGN.. The simple moving average for the past 20 days is -6.42% for LEGN’s stock, with a -24.63% simple moving average for the past 200 days.
Is It Worth Investing in Legend Biotech Corp ADR (NASDAQ: LEGN) Right Now?
Additionally, the 36-month beta value for LEGN is 0.18. There are mixed opinions on the stock, with 11 analysts rating it as a “buy,” 10 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for LEGN is 181.19M and currently, short sellers hold a 3.72% ratio of that float. The average trading volume of LEGN on May 14, 2025 was 1.35M shares.
LEGN) stock’s latest price update
Legend Biotech Corp ADR (NASDAQ: LEGN)’s stock price has dropped by -4.01 in relation to previous closing price of 32.38. Nevertheless, the company has seen a loss of -0.92% in its stock price over the last five trading days. seekingalpha.com reported 2025-05-13 that Legend Biotech Corporation (NASDAQ:LEGN ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Caroline Paul – Associate Director, IR Ying Huang – Chief Executive Officer Jessie Yeung – Interim Chief Financial Officer Mythili Koneru – Chief Medical Officer Guowei Fang – President, R&D Alan Bash – President, CARVYKTI Conference Call Participants Gena Wang – Barclays Jessica Fye – JPMorgan Yaron Werber – TD Cowen Kostas Biliouris – BMO Capital Jonathan Miller – Evercore ISI Leonid Timashev – RBC James Shin – Deutsche Bank Mitchell Kapoor – H.C. Wainright Jeet Mukherjee – BTIG Ashwani Verma – UBS Sean McCutcheon – Raymond James Operator Good day, and thank you for standing by.
Analysts’ Opinion of LEGN
Many brokerage firms have already submitted their reports for LEGN stocks, with Redburn Atlantic repeating the rating for LEGN by listing it as a “Buy.” The predicted price for LEGN in the upcoming period, according to Redburn Atlantic is $86 based on the research report published on October 08, 2024 of the previous year 2024.
Truist, on the other hand, stated in their research note that they expect to see LEGN reach a price target of $88. The rating they have provided for LEGN stocks is “Buy” according to the report published on June 17th, 2024.
H.C. Wainwright gave a rating of “Buy” to LEGN, setting the target price at $73 in the report published on May 24th of the previous year.
LEGN Trading at -8.82% from the 50-Day Moving Average
After a stumble in the market that brought LEGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -48.94% of loss for the given period.
Volatility was left at 4.63%, however, over the last 30 days, the volatility rate increased by 6.09%, as shares sank -3.21% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.76% lower at present.
During the last 5 trading sessions, LEGN fell by -0.92%, which changed the moving average for the period of 200-days by -47.45% in comparison to the 20-day moving average, which settled at $33.21. In addition, Legend Biotech Corp ADR saw -4.49% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LEGN starting from Huang Ying, who proposed sale 6,548 shares at the price of $34.55 back on May 01 ’25. After this action, Huang Ying now owns shares of Legend Biotech Corp ADR, valued at $226,233 using the latest closing price.
Yeung Jessie, the Officer of Legend Biotech Corp ADR, proposed sale 339 shares at $35.28 during a trade that took place back on Mar 25 ’25, which means that Yeung Jessie is holding shares at $11,959 based on the most recent closing price.
Stock Fundamentals for LEGN
Current profitability levels for the company are sitting at:
- -0.37 for the present operating margin
- 0.62 for the gross margin
The net margin for Legend Biotech Corp ADR stands at -0.28. The total capital return value is set at -0.17. Equity return is now at value -15.45, with -10.06 for asset returns.
Based on Legend Biotech Corp ADR (LEGN), the company’s capital structure generated 0.25 points at debt to capital in total, while cash flow to debt ratio is standing at -0.41. The debt to equity ratio resting at 0.34. The interest coverage ratio of the stock is -10.82.
Currently, EBITDA for the company is -113.16 million with net debt to EBITDA at -0.56. When we switch over and look at the enterprise to sales, we see a ratio of 4.65. The receivables turnover for the company is 5.02for trailing twelve months and the total asset turnover is 0.38. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.62.
Conclusion
In conclusion, Legend Biotech Corp ADR (LEGN) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
